© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Precipio, Inc. (PRPO) stock surged +5.12%, trading at $26.91 on NASDAQ, up from the previous close of $25.60. The stock opened at $25.21, fluctuating between $25.21 and $27.41 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 25.21 | 27.41 | 25.21 | 26.91 | 236.33K |
| Sep 09, 2026 | 27.10 | 27.10 | 25.50 | 25.60 | 132.82K |
| Sep 08, 2026 | 26.87 | 27.80 | 25.63 | 27.25 | 304.05K |
| Sep 04, 2026 | 26.11 | 27.90 | 24.48 | 27.40 | 114.54K |
| Sep 03, 2026 | 27.67 | 27.96 | 25.91 | 26.12 | 423.79K |
| Sep 02, 2026 | 27.93 | 28.16 | 26.77 | 27.50 | 237.05K |
| Sep 01, 2026 | 27.41 | 28.80 | 27.06 | 27.77 | 211.24K |
| Aug 31, 2026 | 28.85 | 29.91 | 27.27 | 27.69 | 94.48K |
| Aug 28, 2026 | 29.38 | 30.55 | 28.60 | 28.85 | 205.15K |
| Aug 27, 2026 | 30.30 | 30.39 | 28.85 | 29.29 | 36.68K |
| Aug 26, 2026 | 30.43 | 32.57 | 29.57 | 30.41 | 91.03K |
| Aug 25, 2026 | 30.96 | 31.82 | 30.07 | 30.85 | 258.27K |
| Aug 24, 2026 | 30.45 | 31.41 | 29.54 | 31.12 | 29.69K |
| Aug 21, 2026 | 29.48 | 30.45 | 27.00 | 30.45 | 69.64K |
| Aug 20, 2026 | 27.76 | 29.60 | 27.10 | 29.43 | 365.58K |
| Aug 19, 2026 | 25.01 | 27.85 | 24.63 | 27.85 | 92.81K |
| Aug 18, 2026 | 24.05 | 25.64 | 23.90 | 24.69 | 331.44K |
| Aug 17, 2026 | 23.15 | 26.75 | 22.96 | 23.90 | 49.66K |
| Aug 14, 2026 | 23.24 | 24.48 | 22.52 | 23.50 | 75.81K |
| Aug 13, 2026 | 22.89 | 23.42 | 22.23 | 23.21 | 411.28K |
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
| Employees | 61 |
| Beta | 1.29 |
| Sales or Revenue | $15.20M |
| 5Y Sales Change% | -0.705% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |